VALENCIA, Calif., July 11,
2024 /PRNewswire/ -- Valencia Technologies
Corporation announced today that the Department of Health and Human
Services, Centers for Medicare & Medicaid Services (CMS),
published the 2025 Medicare Hospital Outpatient Prospective Payment
and Ambulatory Surgical Center Payment Systems Proposed Rule with
information relevant to the eCoin® system procedure. The technology
is a pioneering, leadless implantable tibial nerve stimulation
(ITNS) system for treating urgency urinary incontinence (UUI).
CMS adjusts existing Category III CPT code
0816T payment for eCoin implantable tibial nerve stimulation (ITNS)
system
In the Proposed Rule issued Wednesday, July 10, 2024, CMS defined that the
existing Category III CPT code 0816T, which describes the eCoin
ITNS procedure, will remain assigned to Hospital Outpatient
Prospective Payment System Ambulatory Payment Classification (APC)
5464 for Calendar Year 2025, with a proposed unadjusted national
average payment rate of US$21,063, as
referenced in the Addendums A and B of the Proposed Rule.
Notably, due to the efforts of the Valencia Technologies
Reimbursement Team in their dialogue with CMS, a favorable
adjustment to the CY 2024 Ambulatory Surgical Center (ASC) payment
rate was achieved. The proposed national unadjusted ASC payment
rate for CY2025 for code 0816T is $19,464, representing a 38% increase over the
CY2024 rate of $14,122.
The eCoin System is the first and only US Food and Drug
Administration (FDA) PMA approved implantable medical device to
target the tibial nerve for the treatment of urgency urinary
incontinence.
Ann Decker, VP of Reimbursement
for Valencia Technologies, stated, "The cumulative effect of the
proposed 2025 continuation of APC assignment 5464, the improved ASC
payment rate, and the recognition of ITNS as a minimally invasive
OAB treatment option in the recently updated guidelines by the
American Urological Association (AUA) and the Society of
Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction
(SUFU), underscores that the eCoin ITNS system will have a strong
reimbursement pathway throughout 2025 and beyond. I could not be
prouder of the diligence and tenacity of the Valencia Team in
building a robust, sustainable reimbursement foundation that will
allow more patients suffering from UUI to access our innovative
technology. Our efforts are focused on ensuring patient access to
the eCoin ITNS system to find relief from their symptoms."
The eCoin device is a coin-sized neurostimulator implanted
subcutaneously in the lower leg during a minimally invasive,
outpatient procedure utilizing local anesthetic. The eCoin device
contains a primary battery and once activated, automatically
delivers intermittent stimulation to the tibial nerve twice weekly
to reduce UUI symptoms without requiring the need for patient
management. The procedure is less invasive than traditional sacral
neuromodulation surgery for treating UUI, which typically requires
a multi-phase approach, the need for sedation or general
anesthesia, and patient management of an external remote and
possibly other recharging components.
The eCoin system received FDA premarket approval (PMA) in the
USA in March 2022 and is currently available throughout
the United States.
Physicians interested in offering eCoin ITNS therapy may
register for the eCoin Physician Qualification training program
using the eCoin physician website at professionals.eCoin.us.
Patients are encouraged to visit Valencia's patient website at www.eCoin.us for
more information about this novel therapy for UUI.
Forward-looking Statements
Statements made in this
press release that relate to future plans, events, prospects or
performance are forward-looking statements as defined under the
Private Securities Litigation Reform Act of 1995. Words such as
"planned," "expects," "believes," "anticipates," "designed," and
similar words are intended to identify forward-looking statements.
While these forward-looking statements are based on the current
expectations and beliefs of management, such forward-looking
statements are subject to a number of risks, uncertainties,
assumptions and other factors that could cause actual results to
differ materially from the expectations expressed in this press
release. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Except as required by law, Valencia undertakes no obligation to update or
revise any forward-looking statements to reflect new information,
changed circumstances or unanticipated events.
CPT® codes and descriptions are copyright 2023 American Medical
Association (AMA). All rights reserved. CPT® is a registered
trademark of the American Medical Association. Applicable
FARD/DFARS Restrictions Apply to Government Use. Fee schedules,
relative value units, conversion factors and/or related components
are not assigned by the AMA, are not part of CPT®, and the AMA is
not recommending their use. The AMA does not directly or indirectly
practice medicine or dispense medical services. The AMA assumes no
liability for data contained or not contained herein.
Media Contact:
Shawn Graft
sgraft@valenciatechnologies.com
(661) 775-1414
View original content to download
multimedia:https://www.prnewswire.com/news-releases/valencia-technologies-announces-cms-publication-of-2025-medicare-proposed-rule-for-ecoin-procedure-302195193.html
SOURCE Valencia Technologies Corporation